Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced a $84 million Series B financing co-led by Westlake Village BioPartners and OrbiMed.

Other participating investors include Redmile Group, Cormorant Asset Management, Cowen Healthcare Investments, RA Capital, and New Leaf Venture Partners. Electra was previously funded by its parent company, Star Therapeutics.

Electra is building a pipeline of novel therapies targeting SIRP, a family of cell surface receptors on various immune cell types. The company is taking a first-in-class approach to engage SIRP beyond the current drug development efforts in cancer, by targeting specific SIRP proteins to deplete targeted pathological immune cells.